Abstract: Disclosed herein are techniques for implementation of a Hemoglobin A (HBA) assay and an HBA genotyping decision tree matrix in clinical testing. Particularly, aspects are directed to obtaining raw data from the HBA assay performed on a plurality of samples, calculating a first set of probe ratios for each sample based on the raw data, identifying a number of reference samples to be combined as a synthetic reference sample based on the first set of probe ratios, calculating a second set of probe ratios for each sample of the plurality of samples based on the raw data and the synthetic reference sample, and determining, by the decision tree matrix, an HBA genotype for each sample based on the second set of probe ratios for each sample and copy number calling thresholds for sample probe/reference probe ratios associated with each probe of the plurality of probes.

Abstract: Techniques for identifying trending activity on a software-based platform (e.g., an online sportsbook platform) can include a computing system that receives data corresponding to an event occurring at a point in time within the platform. The computing system can identify characteristics associated with the data corresponding to the event and update state data associated with each identified characteristic in a data store maintaining time-series data that represents events that have occurred within the software-based platform. The data can be indexed as a time-series representation based on the point in time associated with the event and on the identified characteristics. The computing system can provide data consumer devices access to the time-series data via application programming interface functions.

Abstract: The present disclosure relates to Fragile X (FRAX) Polymerase Chain Reaction (PCR) assaying techniques. Particularly, aspects are directed to assaying a sample obtained from a subject using the FRAX PCR assay to obtain FRAX PCR raw data. The FRAX PCR assay may utilize a primer that comprises both CGG repeats and an “A” nucleotide at the 3? end and a reverse primer and targets CGG repeat regions in the 5? untranslated region (UTR) of FMR1 gene.

Abstract: The present disclosure relates to Fragile X Syndrome (FXS) clinical testing, and in particular to an FXS AGG interruption polymerase chain reaction (PCR) assay and an AGG interruption genotyping algorithm for implementation into clinical testing. Particularly, aspects are directed to obtaining raw data from the FXS assay performed on a sample, iteratively searching the raw data and identifying one or more AGG peaks on the first allele using a first set of search spaces determined based on an expected AGG peak size, determining a number of CGG repeats downstream of a final AGG interruption and a number of CGG repeats preceding a first AGG interruption on the first allele based on the one or more AGG peaks, and generating an AGG genotype for the first allele based on the number of CGG repeats downstream of the final AGG interruption and the number of CGG repeats preceding the first AGG interruption.

Abstract: The present disclosure relates to a Hemoglobin A (HBA) assay and a HBA genotyping decision tree matrix for implementation into clinical testing. Particularly, aspects are directed to obtaining raw data from the HBA assay performed on a plurality of samples, calculating a first set of probe ratios for each sample based on the raw data, identifying a number of reference samples to be combined as a synthetic reference sample based on the first set of probe ratios, calculating a second set of probe ratios for each sample of the plurality of samples based on the raw data and the synthetic reference sample, and determining, by the decision tree matrix, a HBA genotype for each sample based on the second set of probe ratios for each sample and copy number calling thresholds for sample probe/reference probe ratios associated with each probe of the plurality of probes.

Abstract: The present disclosure relates to Fragile X Syndrome (FXS) clinical testing, and in particular to a FXS AGG interruption polymerase chain reaction (PCR) assay and an AGG interruption genotyping algorithm for implementation into clinical testing. Particularly, aspects are directed to obtaining raw data from the FXS assay performed on a sample, iteratively searching the raw data and identifying one or more AGG peaks on the first allele using a first set of search spaces determined based on an expected AGG peak size, determining a number of CGG repeats downstream of a final AGG interruption and a number of CGG repeats preceding a first AGG interruption on the first allele based on the one or more AGG peaks, and generating a AGG genotype for the first allele based on the number of CGG repeats downstream of the final AGG interruption and the number of CGG repeats preceding the first AGG interruption.